Tris Pharma Reports Positive Topline Data from Clinical Study of Investigational Pain Therapy Cebranopadol Showing Significantly Less Potential for Abuse Versus Tramadol and Oxycodone

-- Study evaluating human abuse potential demonstrates that the likeability of cebranopadol administered orally in nondependent recreational opioid users was...

Related Keywords

United States ,Ketan Mehta ,Tris Pharma Inc ,Us Food Drug Administration ,Prnewswire Tris Pharma Inc ,World Health Organization Study In Primary Care ,Fast Track Designation ,Drug Administration ,Visual Analog Scale ,About Cebranopadol ,Hyperactivity Disorder ,Chronic Pain ,High Impact Chronic Pain Among Adults ,Mortal Wkly ,World Health Organization Study ,Primary Care ,Tris Pharma ,Nc ,